Abstract
Granulocyte colony-stimulating factor (G-CSF) reduces the severity and duration of neutropenia associated with cancer chemotherapy [1–5]. In the pivotal phase III trial in patients with small cell lung cancer, patients were randomized to either G-CSF or placebo following combination chemotherapy in a double-blind fashion [3]. A significant difference in the cumulative risk of febrile neutropenia (FN) between the control (77%) and the G-CSF (40%) groups was observed despite the allowed use of secondary G-CSF prophylaxis after an initial occurrence of FN in the control group (P < 0.001). Several additional clinical trials of prophylactic G-CSF in patients with various malignancies receiving different treatment regimens have been reported [6–11].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414–22.
Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol. 1989;7:1554–62.
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–70.
Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319–24.
Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88:1907–29.
Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood. 1992;80:1430–6.
Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995;13:2629–36.
Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood. 1997;89:3974–9.
Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d‘Etude des Lymphomes de l‘Adulte. Leuk Lymphoma. 1997;25:289–300.
Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716–24.
Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406–11.
Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–66.
Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316–22.
Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.
Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18:539–44.
Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect. 2001;42:120–5.
Darmon M, Azoulay E, Alberti C, et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 2002;28:1775–80.
Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–59.
Carratala J, Roson B, Fernandez-Sevilla A, et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998;158:868–72.
Rossini F. Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer. 1996;4:46–50.
Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286–91.
Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005].
Burton C, Linch D, Hoskin P, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin’s lymphoma. Br J Cancer. 2006;94:806–13.
Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–53.
Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:540–55.
Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997;336:1776–80.
Dunlop DJ, Eatock MM, Paul J, et al. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin’s disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol). 1998;10:107–14.
Bassan R, Lerede T, Di Bona E, et al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma. 1997;26:153–61.
Crawford J, Kreisman H, Garewal H, et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol. 1997;8:1117–24.
Lokich JJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol. 2006;29:361–3.
Kaufman PA, Paroly W, Rinaldi D, et al. Randomized double-blind phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat. 2004;88(1):S59.
Bohlius J, Reiser M, Schwarzer G, et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol. 2003;122:413–23.
Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995;16:62–73.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–45.
Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98.
Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Earlbaum Associates; 1988.
Gatzemeier U, Kleisbauer JP, Drings P, et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol. 2000;23:393–400.
Gebbia V, Testa A, Valenza R, et al. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother. 1993;5:186–90.
Gebbia V, Valenza R, Testa A, et al. A prospective randomized trial of thymopentin versus granulocyte – colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res. 1994;14:731–4.
Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:3041–50.
Ösby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840–8.
Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol. 2005;23:7974–84.
Muhonen T, Jantunen I, Pertovaara H, et al. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol. 1996;19:232–4.
Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.
Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–214.
Dale DC, McCarter GC, Crawford J, et al. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Comp Cancer Net. 2003;1:440–54.
Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1108–17.
Russo A, Autelitano M, Re BL. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1826–7.
Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24:2991–7.
Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857–64.
Calhoun EA, Schumock GT, McKoy JM, et al. Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics. 2005;23:767–75.
Cosler LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy. 2004;24:488–94.
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–41.
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.
Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881–93.
Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–47.
Kummel S, Krocker J, Kohls A, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer. 2006;94:1237–44.
Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–95.
Woll PJ, Hodgetts J, Lomax L, et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol. 1995;13:652–9.
Hidalgo M, Mendiola C, Lopez-Vega JM, et al. A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998;83:719–25.
Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer. 1997;75:306–9.
Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19:2638–46.
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471–508.
Gerhartz HH, Engelhard M, Brittinger G, et al. Recombinant human granulocyte–macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin’s lymphomas. Semin Oncol. 1994;21:25–28.
Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005;5:14.
Olkin I, Sampson A. Comparison of meta-analysis versus analysis of variance of individual patient data. Biometrics. 1998;54:317–22.
Mathew T, Nordstrom K. On the equivalence of meta-analysis using literature and using individual patient data. Biometrics. 1999;55:1221–3.
Angelillo IF, Villari P. Meta-analysis of published studies or meta-analysis of individual data? Caesarean section in HIV-positive women as a study case. Public Health. 2003;117:323–8.
Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995;13:1564–1771.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kuderer, N.M. (2010). Meta-Analysis of Randomized Controlled Trials of Granulocyte Colony-Stimulating Factor Prophylaxis in Adult Cancer Patients Receiving Chemotherapy. In: Lyman, G., Dale, D. (eds) Hematopoietic Growth Factors in Oncology. Cancer Treatment and Research, vol 157. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7073-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7073-2_8
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-7072-5
Online ISBN: 978-1-4419-7073-2
eBook Packages: MedicineMedicine (R0)